New Horizon Health Ltd is a China-based investment holding company principally engaged in the research, development, clinical development, test operation and commercialization of screening products for colorectal cancer, gastric cancer and cervical cancer. The Company distributes its ColoClear, Pupu tube and other products to customers through its own network, contracted sales organisations (CSOs) and Internet sales or e-platform operated by healthcare clinics. The Companyâs Youyou Tube (a stool-based self-checking gastric cancer screening test) and CerviClear (a non-invasive urine cervical cancer home screening test) are under development.

Employees

1,041

Sector

Medical Equipment, Supplies & Distribution

Calendar

2025-03-16 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.14

Average target price

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 04:08:30 2024-03-27 am EDT			5-day change	1st Jan Change
14.14 ^HKD	-19.75%		-.--%	-38.92%

Sep. 09	New Horizon Health Auditor Resigns	MT
Sep. 09	New Horizon Health CFO Resigns	MT

Capitalization	5.86B 831M 6.47B	P/E ratio 2023 *	27.8x	P/E ratio 2024 *	27.2x
Enterprise value	5.81B 823M 6.42B	EV / Sales 2023 *	2.91x	EV / Sales 2024 *	-
Free-Float	76.11%	Yield 2023 *	-	Yield 2024 *	-

New Horizon Health Auditor Resigns	Sep. 09	MT
New Horizon Health CFO Resigns	Sep. 09	MT
New Horizon Health Limited Announces Joint Company Secretary Changes	Sep. 09	CI
New Horizon Health Limited Announces Resignation of Yu Gao as Chief Financial Officer, Effective September 30, 2024	Sep. 09	CI
New Horizon Health Limited Announces Board Appointments	Apr. 08	CI
New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023	Mar. 28	CI
New Horizon Health Forecasts Up to 168% Rise in 2023 Revenue	Jan. 22	MT
New Horizon Health Limited Provides Group Earnings Guidance for the Year Ended December 31, 2023	Jan. 22	CI
New Horizon Health Swings to Profit in H1 as Revenue Soars 265%	23-08-22	MT
New Horizon Health Limited commences an Equity Buyback Plan for 45,759,199 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.	23-08-22	CI
New Horizon Health Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
New Horizon Health Rejects Short Seller's Allegations	23-08-17	MT
New Horizon Health Forecasts Swing to Profit in H1; Shares Plunge 9%	23-08-07	MT

UBS Adjusts New Horizon Health's Price Target to HK$51 From HK$47, Keeps at Buy	22-07-20	MT
UBS Adjusts New Horizon Health’s Price Target to HK$47 From HK$52 Keeps at Buy	22-03-24	MT

New Horizon Health Limited Stock

Equities

6606

KYG6485S1021

Medical Equipment, Supplies & Distribution

Valuation: New Horizon Health Limited

Chart: New Horizon Health Limited

Latest news: New Horizon Health Limited

Analysts' recommendations: New Horizon Health Limited

Press Releases: New Horizon Health Limited

News in other languages: New Horizon Health Limited

Quotes and Performance

Course Extremes

Managers and Directors: New Horizon Health Limited

ETFs: New Horizon Health Limited

Diagnostic & Testing Substances

Financials

Company Profile

Income Statement and Estimates

Analysts' Consensus

Quarterly earnings, Rate of surprise

Qiming Venture Partners' Portfolio Company UBTech Listed on Hong Kong Stock Exchange	Dec. 29	PR
EC Healthcare Collaborates with New Horizon Health to form Strategic Partnership To Jointly Launch CerviClear in Hong Kong	23-03-24	AQ
New Horizon cuts ribbon on cancer screening research center	23-02-24	AQ
New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82%	22-08-19	AQ
PRESS RELEASE : Epigenomics AG publishes financial results for the first nine months 2021	21-11-10	DJ

Epigenomics AG veröffentlicht Finanzergebnisse für die ersten neun Monate 2021	21-11-10
DGAP-Adhoc : Epigenomics AG: Abschluss von Biobank Sale Agreement und Anhebung der Prognose	21-08-17
UPDATE/MÄRKTE ASIEN/Schanghai zum Wiederstart nur anfangs sehr fest	21-02-18
MÄRKTE ASIEN/Schanghai zum Wiederstart nur anfangs sehr fest	21-02-18
Westpac Banking : MÄRKTE ASIEN/Leichter - Schanghai zum Wiederstart fester	21-02-18

Director	Title	Age	Since
Ye Qing Zhu CEO	Chief Executive Officer	52	18-06-06
Yi You Chen FOU	Founder	-	18-06-06
Yu Gao DFI	Director of Finance/CFO	41	20-05-31

Name	Weight	AuM	1st Jan change	Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD	1.12%	4 M€	-27.92%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD	0.11%	2 M€	-14.14%
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD	0.01%	4 M€	-4.41%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.01%	99 M€	+8.12%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
NEW HORIZON HEALTH LIMITED	-19.75%	-.--%	-27.41%	-64.65%	814M
BIOMÉRIEUX	0.00%	-1.73%	+16.95%	-3.35%	14.22B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-1.90%	-0.67%	+6.46%	+48.88%	7.62B
LANTHEUS HOLDINGS, INC.	+0.39%	+4.35%	+71.72%	+324.06%	7.54B
DIASORIN S.P.A.	-1.20%	-1.01%	+13.98%	-48.58%	6.19B
VITROLIFE AB	+0.04%	-1.78%	+64.68%	-51.75%	3.23B
AUTOBIO DIAGNOSTICS CO., LTD.	+1.36%	+0.08%	-17.00%	-27.44%	3.16B
ANDON HEALTH CO., LTD.	+0.32%	-2.34%	+9.31%	+467.75%	2.62B
MYRIAD GENETICS, INC.	-0.63%	+7.20%	+62.96%	-16.10%	2.57B
10X GENOMICS, INC.	+6.34%	+4.12%	-49.52%	-85.64%	2.83B
Average	-2.00%	-1.60%	+15.21%	+54.32%	5.08B
Weighted average by Cap.	-0.54%	+0.03%	+21.59%	+61.07%

	2023 *	2024 *
Net sales	2.01B 285M 2.22B	-
Net income	218M 30.9M 241M	218M 30.9M 241M
Net Debt	-	-

1 day	-19.75%
6 months	-24.63%
Current year	-38.92%

Manager	Title	Age	Since
Yi You Chen FOU	Founder	-	18-06-06
Danke Yu BRD	Director/Board Member	54	21-02-16
Hong Wu BRD	Director/Board Member	66	21-02-16